About
Arjuna Therapeutics develops a novel class of cancer therapies focused on targeting mitochondrial-specific antioxidants to extend the lifespan of patients with late-stage clinical cancers, using their lead drug Ag5 which acts as a catalyst within cellular structures.
Explore Arjuna Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.